Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets

Aug. 24, 2010 - PRLog -- Needham, MA — Epigenetics is a rapidly growing field with promising implications for treatment of cancer and potentially other diseases. Research interest in epigenetics has exploded in recent years, and considerable progress has been made in the commercialization of discoveries in this field. “Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets,” a CHI Insight Pharma Report, examines the industry’s current and projected markets for epigenetic diagnostic and therapeutic products, industry trends, and major challenges and hurdles.











Key topics:

Chapter 1: Introduction
Chapter 2: Overview of epigenetics
Chapter 3: Diagnostic companies in epigenetics
Chapter 4: Major disease/conditions targeted by new and/or emerging epigenetic drugs
Chapter 5: Epigenetic drugs on the market and in development
Chapter 6: Business considerations in epigenetics
Chapter 7: Interview transcripts
References
Company index with web addresses
Figures & Tables

For more information and to purchase this report, go to:
http://www.insightpharmareports.com/reports_report.aspx?i...

Related Reports:
Molecular Diagnostics: A Dynamic and Rapidly Broadening Market
http://www.insightpharmareports.com/reports_report.aspx?r...

Multiplex Assays: Evolving Technologies, Applications, and Future Directions
http://www.insightpharmareports.com/reports_report.aspx?r...

About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.  www.InsightPharmaReports.com

Contact:
James Prudhomme
Cambridge Healthtech Institute
Tel: +1 781-972-5486
jprudhomme@healthtech.com

# # #

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. www.chicorporate.com